GERN
Geron Corporation
$1.28
+0.02
(+1.59%)
Mkt Cap
821.15M
Volume
6,611,918
52W Range
1.04-2.01
Sector
Healthcare
Beta
0.68
EPS (TTM)
-0.10
P/E Ratio
-10.26
Revenue (TTM)
196.12M
Rev Growth (5Y)
+273.6%
EPS Growth (5Y)
N/A
Company Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 183.88M | 76.99M | 237,000 | 596,000 | 1.39M | 253,000 | 460,000 | 1.07M | 1.06M | 6.16M | 36.37M | 1.15M |
| Net Income | (85.78M) | (174.57M) | (184.13M) | (141.90M) | (116.11M) | (75.62M) | (68.55M) | (27.02M) | (27.92M) | (29.54M) | 46,000 | (35.67M) |
| EPS | -0.13 | -0.27 | -0.32 | -0.37 | -0.37 | -0.28 | -0.33 | -0.15 | -0.18 | -0.19 | 0.00 | -0.23 |
| Free Cash Flow | (111.09M) | (219.30M) | (168.57M) | (127.81M) | (95.76M) | (67.05M) | (44.24M) | (21.02M) | (20.56M) | (18.43M) | N/A | N/A |
| FCF / Share | -0.17 | -0.34 | -0.30 | -0.34 | -0.29 | -0.25 | -0.23 | -0.12 | -0.13 | -0.12 | N/A | N/A |
| Operating CF | (111.04M) | (218.62M) | (167.74M) | (127.38M) | (95.56M) | (66.65M) | (43.83M) | (21.01M) | (20.56M) | (18.37M) | N/A | N/A |
| Total Assets | 570.54M | 593.78M | 394.08M | 190.57M | 226.03M | 270.73M | 165.52M | 185.28M | 110.31M | 130.25M | N/A | N/A |
| Total Debt | 251.57M | 121.72M | 85.90M | 55.75M | 55.00M | 29.72M | 2.55M | 0 | 0 | 0 | N/A | N/A |
| Cash & Equiv | 79.44M | 79.02M | 70.02M | 56.84M | 34.87M | 9.93M | 13.64M | 10.84M | 16.60M | 13.08M | N/A | N/A |
| Book Value | 225.87M | 280.32M | 247.95M | 80.00M | 126.42M | 210.95M | 135.16M | 177.73M | 103.80M | 122.38M | N/A | N/A |
| Return on Equity | -0.38 | -0.62 | -0.74 | -1.77 | -0.92 | -0.36 | -0.51 | -0.15 | -0.27 | -0.24 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.84M | 48.02M | 47.23M | 49.04M | 39.60M | 47.54M | 28.27M | 882,000 | 304,000 | 23,000 | 164,000 | 29,000 |
| Net Income | (3.64M) | (31.14M) | (18.43M) | (16.38M) | (19.84M) | (25.35M) | (26.45M) | (67.38M) | (55.39M) | (51.97M) | (44.80M) | (49.23M) |
| EPS | -0.01 | -0.05 | -0.03 | -0.02 | -0.03 | -0.04 | -0.04 | -0.10 | -0.09 | -0.09 | -0.08 | -0.09 |
| Free Cash Flow | (63.16M) | (22.10M) | (13.49M) | (27.55M) | (47.98M) | (43.80M) | (58.94M) | (53.68M) | (62.87M) | (41.00M) | (51.03M) | (29.80M) |
| FCF / Share | -0.09 | -0.03 | -0.02 | -0.04 | -0.07 | -0.07 | -0.09 | -0.08 | -0.10 | -0.07 | -0.09 | -0.05 |
| Operating CF | (62.91M) | (22.07M) | (13.58M) | (27.41M) | (47.98M) | (43.95M) | (58.94M) | (53.48M) | (62.25M) | (40.94M) | (50.84M) | (29.60M) |
| Total Assets | 534.12M | 570.54M | 567.38M | 555.20M | 562.45M | 593.78M | 444.95M | 449.40M | 482.07M | 394.08M | 413.02M | 415.30M |
| Total Debt | 251.84M | 251.57M | 121.92M | 121.84M | 121.78M | 121.72M | 87.26M | 87.04M | 86.53M | 85.90M | 56.02M | 55.93M |
| Cash & Equiv | 70.78M | 79.44M | 78.12M | 77.73M | 83.75M | 79.02M | 60.34M | 116.94M | 189.76M | 71.14M | 30.71M | 56.90M |
| Book Value | 229.11M | 225.87M | 248.71M | 259.53M | 268.24M | 280.32M | 292.28M | 306.69M | 344.87M | 247.95M | 290.61M | 298.43M |
| Return on Equity | -0.02 | -0.14 | -0.07 | -0.06 | -0.07 | -0.09 | -0.09 | -0.22 | -0.16 | -0.21 | -0.15 | -0.16 |
GERN News
Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026
Geron Corporation (GERN) Q1 2026 Earnings Call Transcript
Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
Geron Plans to Present at Upcoming Investor Conferences
Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026